Overview

* Prothena Q3 2025 net loss narrowed to $36.5 mln, with collaboration revenue of $2.4 mln

* Company highlighted Phase 3 trials for prasinezumab and coramitug

* Prothena ( PRTA ) to hold EGM for potential share redemption program in 2026

Outlook

* Prothena ( PRTA ) expects 2025 net cash use of $170 to $178 mln

* Company anticipates ending 2025 with $298 mln in cash

* Prothena ( PRTA ) plans share redemption program vote in Nov 2025

Result Drivers

* R&D EXPENSES - Decrease in R&D expenses attributed to lower clinical trial and personnel costs

* COLLABORATION REVENUE - Revenue primarily from Bristol Myers Squibb collaboration related to PRX019 Phase 1 trial

* CASH POSITION - Strong cash position supports pipeline advancement

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $2.42

Collabor mln

ation

Revenue

Q3 Net -$36.54

Income mln

Q3 $42.66

Operatin mln

g

Expenses

Q3 -$36.91

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Prothena Corporation PLC ( PRTA ) is $14.50, about 29.2% above its November 5 closing price of $10.27

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)